People with rare diseases get ‘unequal treatment’ from ‘inflexible’ NHS drug regulator, warns report calling for system reform

20 February 2019 – Daily Mail

The National Institute for Health and Care Excellence (NICE) gives guidance on how to improve health care, including advising on how cost-effective treatments are.

However, it has been branded ‘inflexible’ towards those who have rare diseases.

MAP BioPharma, a company which provides insights into the pharmaceutical market, found that 13% of rare disease medicines make it through assessments, compared to 68% of medicines for common diseases.


%d bloggers like this: